In an expert interview at ESMO 2018, Dr András Illés discusses the current research behind RGB-02, a biosimilar pegfilgrastim for the treatment of chemotherapy-induced neutropenia. Biosimilars are subjected to rigorous clinical trials to ensure equivalence to the originator drug in terms of safety, efficacy, and pharmacokinetic and pharmacodynamic profiles. So far two sets of results have been published for RGB-02 and these show that it is comparable to the originator. The benefits of biosimilars are that they are often cheaper than the originator drug and mean more patients will have access to treatment.
1. What was the background and rationale behind the three clinical trials investigating the RGB-02 biosimilar pegfilgrastim? (0:11)
2. What were the key findings and outcomes? (1:18)
3. How will these findings impact on clinical practice and patient outcomes? (1:53)
4. What are the next steps in this area of research over the coming years? (2:31)
Speaker disclosures: András Illés has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.